MacroGenics, Inc.
MGNXNASDAQHealthcare● Active
$3.88
$-0.03(-0.77%)
Market Cap$246624828
P/E Ratio—
52W High$4.64
52W Low$1.185
MacroGenics, Inc. (MGNX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MGNX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.58
Est. -$0.57 · -1.8%
Revenue
$0.02B
Est. $0.02B · +36.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
MGNX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.08 | — | — | — | $0.06B | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$0.57 | -$0.58 | -1.8% | $0.02B | $0.02B | +36.3% |
| ▲ Q1 FY2026 | Mar 9, 2026 | -$0.42 | -$0.22 | +47.6% | $0.04B | $0.03B | +19.2% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.48 | $0.27 | +156.3% | $0.07B | $0.03B | +161.9% |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.59 | -$0.57 | +3.4% | $0.02B | $0.02B | -8.9% |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.61 | -$0.65 | -6.6% | $0.01B | $0.01B | +12.1% |
| ▼ Q1 FY2025 | Mar 20, 2025 | -$0.23 | -$0.25 | -8.7% | $0.02B | $0.03B | -48.1% |
| ▲ Q4 FY2024 | Nov 5, 2024 | $0.21 | $0.90 | +328.6% | $0.11B | $0.03B | +238.7% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$0.58
EPS Est.
-$0.57
EPS Surpr.
-1.8%
Revenue
$0.02B
Q1 FY2026
Mar 9, 2026Beat
EPS Actual
-$0.22
EPS Est.
-$0.42
EPS Surpr.
+47.6%
Revenue
$0.04B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
$0.27
EPS Est.
-$0.48
EPS Surpr.
+156.3%
Revenue
$0.07B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.57
EPS Est.
-$0.59
EPS Surpr.
+3.4%
Revenue
$0.02B
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.65
EPS Est.
-$0.61
EPS Surpr.
-6.6%
Revenue
$0.01B
Q1 FY2025
Mar 20, 2025Miss
EPS Actual
-$0.25
EPS Est.
-$0.23
EPS Surpr.
-8.7%
Revenue
$0.02B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
$0.90
EPS Est.
$0.21
EPS Surpr.
+328.6%
Revenue
$0.11B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.87 | $-0.34 | $0.02 | 1 |
| Q3 FY2027 | $-0.87 | $-0.34 | $0.02 | 1 |
| Q2 FY2027 | $-1.09 | $-0.42 | $0.02 | 1 |
| Q1 FY2027 | $-0.98 | $-0.38 | $0.02 | 1 |
| Q4 FY2026 | $-0.63 | $-0.25 | $0.01 | 1 |
| Q3 FY2026 | $-2.74 | $-0.40 | $1.36 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.1B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -1.8% | $3.52 | $3.45 | -1.99% |
| ▲ Q1 FY2026 | Mar 9, 2026 | +47.6% | $2.23 | $2.36 | +5.83% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +156.3% | $1.52 | $1.47 | -3.29% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +3.4% | $1.66 | $1.62 | -2.41% |
| ▼ Q2 FY2025 | May 13, 2025 | -6.6% | $1.59 | $1.54 | -3.14% |
| ▼ Q1 FY2025 | Mar 20, 2025 | -8.7% | $2.18 | $2.10 | -3.67% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +328.6% | $3.70 | $3.77 | +1.89% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -50.9% | $3.64 | $3.38 | -7.14% |
Q2 FY2026-1.99%
Report Date
May 13, 2026
EPS Beat/Miss
-1.8%
Price Before
$3.52
Price After
$3.45
Q1 FY2026+5.83%
Report Date
Mar 9, 2026
EPS Beat/Miss
+47.6%
Price Before
$2.23
Price After
$2.36
Q4 FY2025-3.29%
Report Date
Nov 12, 2025
EPS Beat/Miss
+156.3%
Price Before
$1.52
Price After
$1.47
Q3 FY2025-2.41%
Report Date
Aug 14, 2025
EPS Beat/Miss
+3.4%
Price Before
$1.66
Price After
$1.62
Q2 FY2025-3.14%
Report Date
May 13, 2025
EPS Beat/Miss
-6.6%
Price Before
$1.59
Price After
$1.54
Q1 FY2025-3.67%
Report Date
Mar 20, 2025
EPS Beat/Miss
-8.7%
Price Before
$2.18
Price After
$2.10
Q4 FY2024+1.89%
Report Date
Nov 5, 2024
EPS Beat/Miss
+328.6%
Price Before
$3.70
Price After
$3.77
Q3 FY2024-7.14%
Report Date
Aug 7, 2024
EPS Beat/Miss
-50.9%
Price Before
$3.64
Price After
$3.38
Avg Beat Reaction+0.50%
Avg Miss Reaction-3.99%
Beat Rate4 / 8 quarters
Largest Move-7.14% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MGNX ends December
MacroGenics, Inc. (MGNX) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.58 — missing the analyst consensus of $-0.57 by -1.8%. The next MGNX earnings date is expected around September 1, 2026.
Each quarter, investors track MGNX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MGNX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MGNX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MGNX earnings · 5 questionsMacroGenics, Inc.'s next earnings report is expected around September 1, 2026. MGNX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MGNX historically reports after market close (AMC).
MGNX earnings datewhen is MGNX earningsMGNX next earnings datewhen does MGNX report earningsMGNX earnings calendar
▸ Source: FMP · MacroGenics, Inc. SEC filings · US GAAP · MacroGenics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026